Moderna (NASDAQ:MRNA) Shares Down 4.7% - Here's What Happened

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares were down 4.7% during mid-day trading on Monday . The company traded as low as $37.08 and last traded at $37.56. Approximately 2,802,809 shares were traded during trading, a decline of 77% from the average daily volume of 12,083,261 shares. The stock had previously closed at $39.42.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MRNA shares. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. The Goldman Sachs Group cut shares of Moderna from a "buy" rating to a "neutral" rating and lowered their target price for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Piper Sandler restated an "overweight" rating and set a $69.00 price target (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Evercore ISI lowered their price objective on Moderna from $60.00 to $50.00 and set an "in-line" rating on the stock in a research note on Monday, January 27th. Finally, Hsbc Global Res upgraded Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Moderna currently has an average rating of "Hold" and a consensus price target of $67.26.

Moderna Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The company's 50 day moving average price is $40.42 and its 200 day moving average price is $59.05. The firm has a market capitalization of $12.93 billion, a P/E ratio of -5.77 and a beta of 1.59.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the company earned ($1.39) EPS. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.18 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares of the company's stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,664 shares of company stock worth $115,210 over the last 90 days. Insiders own 15.20% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. Wilmington Savings Fund Society FSB increased its holdings in Moderna by 295.0% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock valued at $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc bought a new stake in shares of Moderna in the 4th quarter valued at about $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock valued at $44,000 after acquiring an additional 389 shares during the period. Finally, Blue Trust Inc. boosted its stake in Moderna by 53.1% during the 4th quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock worth $47,000 after acquiring an additional 388 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.